PipelineRSSMay 1
FDA Permits Expanded Access for Investigational Pancreatic Cancer Drug
The FDA has given approval for Revolution Medicines to offer an experimental pancreatic cancer drug called daraxonrasib to patients outside of clinical trials through a special program called expanded access. This program allows patients with serious illnesses who have no other treatment options to try investigational drugs before they are fully approved. This is an important step forward for patients with pancreatic cancer who may benefit from this new treatment.
WHY IT MATTERSPatients with advanced pancreatic cancer who have exhausted standard treatment options may now have access to daraxonrasib through expanded access, potentially offering a new therapeutic option while the drug completes its clinical development.